Pfizer Ventures Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 6
- Investments
- 165
- Portfolio
- 50
- Exits
- 82
Pfizer Ventures General Information
Description
Founded in 2004, Pfizer Ventures is the corporate venture capital arm of Pfizer Inc. based in New York, New York. The firm prefers to invest in seed-stage, early-stage, and later-stage companies. It prefers to invest in companies operating in transformative therapeutics medicines, platform technologies, diagnostics, drug delivery, vaccines, and the pharmaceutical services sectors across the United States.
Contact Information
Website
www.pfizerventures.com
Year Founded
2004
Investor Status
Actively Seeking New Investments
Trade Association
National Venture Capital Association (NVCA)
Primary Investor Type
Corporate Venture Capital
Primary Office
- 235 East 42nd Street
- New York, NY 10017
- United States
+1 (212) 000-0000
Pfizer Ventures Investments (165)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Arkuda Therapeutics | 25-Jan-2022 | Early Stage VC | 0000 | Drug Discovery | Generating Revenue | 00000000000 0'0000000 00.0 |
| 0000000 | 23-Dec-2021 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | 00000 0000000 00.0 |
| 00000 000000000000 | 08-Nov-2021 | 0000 | 000.00 | Drug Discovery | Clinical Trials - Phase 1 | 0000 00-000000 00.0 |
| 000000 00000000000 | 13-Oct-2021 | 00000 00000 | 0000 | Drug Delivery | Generating Revenue | 0000 00-000000 00.0 |
| 00000000 000000000 | 16-Sep-2021 | 00000 00000 | 000.00 | Drug Delivery | Generating Revenue | |
| 00000000 000000000 | 26-Aug-2021 | 0000 | 0000 | Drug Discovery | Profitable | 00000 0000000 00.0 |
| 00000 000000000000 | 18-Aug-2021 | 00000 00000 | 0000 | Drug Discovery | Pre-Clinical Trials | 000000 0000000 00.0 |
| 000000000 00000000 | 13-Aug-2021 | 00000 00000 | 0000 | Drug Discovery | Pre-Clinical Trials | 00000000000 0'0000000 00.0 |
| Strata Oncology | 28-Jul-2021 | Later Stage VC | 0000 | Decision/Risk Analysis | Generating Revenue | 00000000000 0'0000000 00.0 |
| Artios | 23-Jul-2021 | Later Stage VC | 00000 | Drug Discovery | Generating Revenue | 0000000 000000 00.0 |
Pfizer Ventures Exits (82)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| 4DMT | 01-Nov-2021 | Public Investment 2nd Offering | 00000 |
| 00000 00000000 | 08-Oct-2021 | 000 | 00000 |
| 0-000 000000000000 | 15-Jul-2021 | 0000000000 | |
| 00000000 | 01-Jul-2021 | 000000000 00000000 | |
| 0000 000000000000 | 16-May-2021 | 000000000000000000 | 000.00 |
| 000000000 | 09-Apr-2021 | 000 | 00000 |
| 000000 00000000000 | 01-Apr-2021 | 000000000 00000000 | |
| 0000 0000000000000 | 05-Feb-2021 | 000 | 00000 |
| Yumanity Therapeutics | 22-Dec-2020 | Reverse Merger | |
| BioAtla | 16-Dec-2020 | IPO | 00000 |
Pfizer Ventures Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialPfizer Ventures Team (11)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Denis Patrick Ph.D | Managing Partner & Vice President, WRDM | 0 | 0 | New York, NY | |
| Barbara Dalton Ph.D | Vice President, WWBD & Senior Managing Partner | 00 | 0 | 0 | New York, NY |
| Christopher O'Donnell Ph.D | Partner & Executive Director, WRDM | 0 | 0 | New York, NY | |
| Michael Baran Ph.D | Partner & Executive Director, WRDM | 0 | 0 | New York, NY | |
| Rana Al-Hallaq Ph.D | Partner & Senior Director, WWBD | 0 | 0 | New York, NY |
Pfizer Ventures Co-Investors (238)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Alexandria Venture Investments | 12 | 0 | 00 |
|
|
| AbbVie Ventures | 0 | 0 |
|
|
|
| Citadel (Hedge Fund) | 0 | 0 | 0 |
|
|
| HBM Healthcare Investments | 0 | 0 | 0 |
|
|
| HBM Partners | 0 | 0 | 0 |
|
|